Rosenblum Silverman Sutton S F Inc Aclaris Therapeutics, Inc. Transaction History

Rosenblum Silverman Sutton S F Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 Apr 25, 2019	SELL	$5.63 - $7.84 $327,159 - $455,582	-58,110 Closed	0 $0
Q4 2018 Feb 06, 2019	SELL	$6.3 - $15.4 $197,757 - $483,406	-31,390 Reduced 35.07%	58,110 $429,000
Q3 2018 Nov 09, 2018	BUY	$14.38 - $20.89 $223,105 - $324,108	15,515 Added 20.97%	89,500 $1.3 Million
Q2 2018 Aug 13, 2018	BUY	$16.46 - $20.33 $490,261 - $605,529	29,785 Added 67.39%	73,985 $1.48 Million
Q1 2018 May 10, 2018	SELL	$17.08 - $25.64 $34,160 - $51,280	-2,000 Reduced 4.33%	44,200 $774,000

Q4 2017 Feb 01, 2018	BUY	$21.47 - $27.8 $98,762 - $127,880	4,600 Added 11.06%	46,200 $1.14 Million
Q3 2017 Oct 27, 2017	BUY	$23.02 - $28.8 $957,632 - $1.2 Million	41,600	41,600 $1.07 Million

102

53.5M

51K

31.6K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $76M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Rosenblum Silverman Sutton S F Inc , based on Form 13F filings with the SEC.

Stay updated on Rosenblum Silverman Sutton S F Inc with notifications on news.